Floatz logo

FILGRASTIM

Castrate Resistant Prostate Cancer

Case Comprehensive Cancer Centerprotein_peptidePhase 2/3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Castrate Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 3BB
VIPIVOTIDE TETRAXETAN
Jean-Mathieu Beauregard
Phase 2BB
Everolimus
OHSU Knight Cancer Institute
Phase 2BB
Regorafenib
Translational Research in Oncology
Phase 2B
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Barts & The London NHS Trust
Phase 2/3B

View all 24 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →